Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)

Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC) / Saltz, L; Infante, J; Schwartzberg, L; Stephenson, J; Rocha Lima, C; Galimi, Francesco; Dillingham, K; Hsu, M; Wiezorek, J; Fuchs, C.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 27:15(2009). ( 45th Annual Meeting of the American-Society-of-Clinical-Oncology Orlando, FL MAY 29-JUN 02, 2009).